Ahead of Nas­daq de­but, Saurabh Sa­ha pads out the C-suite at Centes­sa, hir­ing a top Dai­ichi Sankyo alum as CMO

Centes­sa is wast­ing no time as­sem­bling the top team in charge of spear­head­ing its port­fo­lio play.

While pre­sum­ably go­ing on vir­tu­al road­shows for its up­com­ing IPO, the biotech put out word that it’s ap­point­ed An­toine Yver, the for­mer head of on­col­o­gy R&D at Dai­ichi Sankyo, as CMO.

With 16 pro­grams in the pipeline — four of which have al­ready reached clin­i­cal stage — that came to­geth­er af­ter Francesco De Ru­ber­tis con­vinced 11 Medicxi star­tups to roll their op­er­a­tions in­to the same com­pa­ny, Yver is sure to hit the ground run­ning. CEO Saurabh Sa­ha clear­ly has no doubt about that, prais­ing his new de­vel­op­ment chief as a “true in­dus­try leader.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER